Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;44(6):1456-1463.
doi: 10.1111/liv.15907. Epub 2024 Mar 15.

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab

Tatsuya Kikuchi  1 , Yasuto Takeuchi  1   2 , Kazuhiro Nouso  3 , Kazuya Kariyama  3 , Kenji Kuwaki  4 , Junichi Toshimori  5 , Shota Iwado  6 , Akio Moriya  7 , Hiroaki Hagihara  8 , Hiroyuki Takabatake  9 , Toshifumi Tada  10 , Tetsuya Yasunaka  11 , Masahiro Sakata  12 , Masahiko Sue  1 , Nozomi Miyake  1 , Takuya Adachi  1 , Nozomu Wada  1 , Hideki Onishi  1 , Hidenori Shiraha  1 , Akinobu Takaki  1 , Motoyuki Otsuka  1
Affiliations

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab

Tatsuya Kikuchi et al. Liver Int. 2024 Jun.

Abstract

Background: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC).

Methods: In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first-line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded. Clinical factors possibly linked to successful transition to conversion therapy and the achievement of cancer-free status were identified.

Results: Fifteen (8.0%) patients underwent conversion therapy. In the conversion group, there was a significantly higher proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B (73.3% versus [vs.] 45.1%; p = .03) and tended to have lower Child-Pugh scores and alpha-fetoprotein levels. Multivariate analysis revealed that BCLC stage was a predictive factor for the implementation of conversion therapy (A or B; odds ratio 3.7 [95% CI: 1.1-13]; p = .04). Furthermore, 10 (66.7%) patients achieved cancer-free status and exhibited a smaller number of intrahepatic lesions at the start of treatment (3.5 vs. 7; p < .01), and a shorter interval between systemic chemotherapy induction and conversion therapy (131 vs. 404 days; p < .01). In addition, the rate of achieving cancer-free status by undergoing surgical resection or ablation therapy was significantly higher (p = .03).

Conclusion: BCLC stage was the sole predictive factor for successful transition to conversion therapy when using combination therapy with atezolizumab and bevacizumab to treat HCC. Furthermore, a small number of intrahepatic lesions and early transition to conversion therapy were associated with the achievement of cancer-free status.

Keywords: Barcelona clinic liver cancer stage; alfa‐fetoprotein; atezolizumab; bevacizumab; cancer‐free; child‐Pugh score; conversion therapy; hepatocellular carcinoma; real‐world practice; tumour response.

PubMed Disclaimer

References

REFERENCES

    1. Yamashita T, Kudo M, Ikeda K, et al. REFLECT – a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55:113‐122.
    1. Fuchigami A, Imai Y, Uchida Y, et al. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle‐term outcome. PLoS One. 2020;15:e0231427.
    1. Kudo M, Ueshima K, Ikeda M, et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. Liver Cancer. 2022;11:354‐367.
    1. Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first‐line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117‐127.
    1. Shimose S, Iwamoto H, Tanaka M, et al. Alternating lenvatinib and trans‐arterial therapy prolongs overall survival in patients with inter‐mediate stage hepatocellular carcinoma: a propensity score matching study. Cancers (Basel). 2021;13(1):160.

MeSH terms

LinkOut - more resources